Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
130.40
-3.24 (-2.42%)
At close: Apr 24, 2026, 4:00 PM EDT
130.49
+0.09 (0.07%)
After-hours: Apr 24, 2026, 7:50 PM EDT
Gilead Sciences Employees
Gilead Sciences had 17,000 employees as of December 31, 2025. The number of employees decreased by 600 or -3.41% compared to the previous year.
Employees
17,000
Change (1Y)
-600
Growth (1Y)
-3.41%
Revenue / Employee
$1,731,941
Profits / Employee
$500,588
Market Cap
161.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17,000 | -600 | -3.41% |
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
| Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
| Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
| Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
| Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
| Jan 31, 2015 | 7,000 | 900 | 14.75% |
| Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
| Jan 31, 2013 | 5,000 | 500 | 11.11% |
| Jan 31, 2012 | 4,500 | 500 | 12.50% |
| Jan 31, 2011 | 4,000 | 148 | 3.84% |
| Jan 31, 2010 | 3,852 | 411 | 11.94% |
| Jan 31, 2009 | 3,441 | 462 | 15.51% |
| Jan 31, 2008 | 2,979 | 464 | 18.45% |
| Jan 31, 2007 | 2,515 | 615 | 32.37% |
| Jan 31, 2006 | 1,900 | 246 | 14.87% |
| Feb 28, 2005 | 1,654 | 229 | 16.07% |
| Feb 27, 2004 | 1,425 | 175 | 14.00% |
| Feb 28, 2003 | 1,250 | 250 | 25.00% |
| Feb 28, 2002 | 1,000 | 150 | 17.65% |
| Feb 28, 2001 | 850 | 90 | 11.84% |
| Dec 31, 1999 | 760 | 467 | 159.39% |
| Dec 31, 1998 | 293 | 4 | 1.38% |
| Dec 31, 1997 | 289 | 41 | 16.53% |
| Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
GILD News
- 3 days ago - Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Business Wire
- 8 days ago - Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - Business Wire
- 11 days ago - PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access - Business Wire
- 11 days ago - Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing - Business Wire
- 15 days ago - AHF Slams Gilead for Role in Florida AIDS Drug Crisis - Business Wire
- 16 days ago - Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Business Wire
- 16 days ago - Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise - Business Wire
- 18 days ago - Gilead Sciences Transcript: M&A announcement - Transcripts